Numerous studies demonstrated the role of TP53 mutations in predicting poor prognosis of advanced NSCLC patients [9,11,12,13,14,15], and this was confirmed also in the subgroup of NSCLC patients carrying EGFR mutations [8,9,16]. Here, TP53 is linked to non-small cell lung carcinoma.